Drug intelligence / Profile preview

SB719125

Development stage: Phase 1
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**SB719125** is an investigational recombinant vaccine developed by GSK for immunotherapy in HER2-overexpressing breast cancer. It consists of a recombinant dHER2 protein (a modified form of the HER2 antigen) combined with the AS15 adjuvant system, designed to elicit robust immune responses against HER2-positive tumor cells. The vaccine was evaluated in early-phase clinical trials for safety, immunogenicity, and preliminary efficacy in high-risk and metastatic breast cancer patients, showing completion of Phase 1 and 2 studies but no further advancement reported.

Other names: dHER2 + AS15 ASCIdHER2 ASCIdHER-2 ASCIdHER 2 ASCI

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SB719125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB719125.

Explore the full profile